activity_id,activity_type,title,status,start_date,end_date,enrollment_target,enrollment_actual,sites,key_endpoints,interim_results,next_milestone
PMCF-001,Registry,CardioStent-X Post-Market Registry (CARDIO-REG),ongoing,2021-01-15,,2000,1450,28 sites across DE/FR/IT/ES,12-month MACE rate; TLR at 12 months; definite/probable stent thrombosis,12-month MACE rate: 6.2% (n=980 evaluable); TLR: 3.1%; definite/probable ST: 0.4%. Results consistent with pre-market clinical data and state-of-the-art.,24-month follow-up data collection (target: Q2 2024)
PMCF-002,Literature review,Systematic literature surveillance for coronary DES safety,ongoing,2023-01-01,,N/A,N/A,N/A,Identification of new safety signals or performance concerns from published literature,12 publications screened; 10 included; no new safety signals identified. Findings consistent with known risk profile.,Next scheduled review: Q4 2024
PMCF-003,Complaint trending,Continuous complaint rate monitoring and trending,ongoing,2019-06-15,,N/A,N/A,N/A,Monthly complaint rate monitoring against UCL; Western Electric rule surveillance,No trend detected in 2023 surveillance period. All monthly rates within control limits. Mean rate: consistent with historical baseline.,Continuous monitoring; next formal review in PSUR-2024
